UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 46,170 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 17.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 218,554 shares of the company’s stock after selling 46,170 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.07% of Amneal Pharmaceuticals worth $1,818,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. FMR LLC lifted its position in shares of Amneal Pharmaceuticals by 25.9% in the 3rd quarter. FMR LLC now owns 203,510 shares of the company’s stock worth $1,693,000 after purchasing an additional 41,882 shares during the period. Quantbot Technologies LP raised its stake in Amneal Pharmaceuticals by 274.8% in the third quarter. Quantbot Technologies LP now owns 111,181 shares of the company’s stock worth $925,000 after buying an additional 81,519 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Amneal Pharmaceuticals by 16.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,404,883 shares of the company’s stock worth $11,689,000 after buying an additional 202,863 shares during the period. Intech Investment Management LLC bought a new stake in Amneal Pharmaceuticals during the 3rd quarter valued at approximately $307,000. Finally, Segall Bryant & Hamill LLC grew its holdings in shares of Amneal Pharmaceuticals by 1.6% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 489,162 shares of the company’s stock worth $4,070,000 after acquiring an additional 7,661 shares during the period. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on AMRX. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target on the stock in a research note on Friday, September 6th. StockNews.com raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 11th. Truist Financial lifted their price target on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, October 2nd. Finally, Piper Sandler upped their price objective on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Amneal Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $10.00.

Amneal Pharmaceuticals Price Performance

AMRX stock opened at $7.83 on Monday. Amneal Pharmaceuticals, Inc. has a 1-year low of $4.74 and a 1-year high of $9.48. The business has a 50 day simple moving average of $8.49 and a two-hundred day simple moving average of $7.91. The company has a market capitalization of $2.43 billion, a price-to-earnings ratio of -11.51 and a beta of 1.12.

Insider Activity at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $8.61, for a total transaction of $375,886.77. Following the sale, the senior vice president now directly owns 13,665 shares of the company’s stock, valued at $117,655.65. The trade was a 76.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 26.56% of the stock is owned by insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.